Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1656)
Drug Name
DA-8159
Synonyms
DA 8159; DA-8159; DA8159; IYFNEFQTYQPVOC-UHFFFAOYSA-N; SB17350; SCHEMBL120993; Udenafil; Udenafil (USAN/INN); Udenafil [USAN:INN]; Zydena; 268203-93-6; 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one; AC1OCFJA; AKOS015902221; BCP07585; CHEBI:135926; CHEMBL2103849; CS-2943; CTK8D3928; DB06267; KS-00001DB6
Indication Pulmonary hypertension [ICD11: BB01] Phase 2/3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 516.7 Topological Polar Surface Area 126
Heavy Atom Count 36 Rotatable Bond Count 11
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
135413547
ChEBI ID
CHEBI:135926
CAS Number
268203-93-6
TTD Drug ID
D01GUS
Formula
C25H36N6O4S
Canonical SMILES
CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
InChI
1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
InChIKey
IYFNEFQTYQPVOC-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
N-desalkyludenafil DM006052
135499879
Oxidation - N-dealkylation 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006516 DA-8159 N-desalkyludenafil Oxidation - N-dealkylation CYP3A4 ... [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[3]
References
1 ClinicalTrials.gov (NCT02304198) Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH.
2 The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
3 The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011 Dec;21(12):820-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.